Search

Your search keyword '"Risinger, Christian Walter"' showing total 9 results
Start Over Author "Risinger, Christian Walter"
9 results on '"Risinger, Christian Walter"'

3. Site-specific detection of advanced glycation endproducts with newly developed single-chain variable fragment antibodies

Author

Wendel, Ulrika Anna Maria, Persson, Nina Emilia, Risinger, Christian Walter, Mirgorodskaya, Ekaterina, Sihlbom, Carina, Bengtsson, Eva, Nodin, Björn, Danielsson, Lena, Welinder, Charlotte, Panico, Maria, Dell, Anne, Haslam, Stuart, Fredrikson, Gunilla Nordin, Jansson, Bo, Blixt, Klas Ola, Wendel, Ulrika Anna Maria, Persson, Nina Emilia, Risinger, Christian Walter, Mirgorodskaya, Ekaterina, Sihlbom, Carina, Bengtsson, Eva, Nodin, Björn, Danielsson, Lena, Welinder, Charlotte, Panico, Maria, Dell, Anne, Haslam, Stuart, Fredrikson, Gunilla Nordin, Jansson, Bo, and Blixt, Klas Ola

Published
2017

4. Epitope mapping of a new anti-Tn antibody detecting gastric cancer cells

Author

Persson, Nina, Stuhr-Hansen, Nicolai, Risinger, Christian Walter, Mereiter, Stefan, Polonia, Antonio, Polom, Karol, Kovács, András, Roviello, Franco, Reis, Celso A., Welinder, Charlotte, Danielsson, Lena, Jansson, Bo, Blixt, Klas Ola, Persson, Nina, Stuhr-Hansen, Nicolai, Risinger, Christian Walter, Mereiter, Stefan, Polonia, Antonio, Polom, Karol, Kovács, András, Roviello, Franco, Reis, Celso A., Welinder, Charlotte, Danielsson, Lena, Jansson, Bo, and Blixt, Klas Ola

Published
2017

6. Immunization with DNA plasmids coding for crimean-congo hemorrhagic fever virus capsid and envelope proteins and/or virus-like particles induces protection and survival in challenged mice

Author

Hinkula, Jorma, Devignot, Stéphanie, Åkerström, Sara, Karlberg, Helen, Wattrang, Eva, Bereczky, Sándor, Mousavi-Jazi, Mehrdad, Risinger, Christian Walter, Lindegren, Gunnel, Vernersson, Caroline, Paweska, Janusz, van Vuren, Petrus Jansen, Blixt, Klas Ola, Brun, Alejandro, Friedemann, Weber, Mirazimi, Ali, Hinkula, Jorma, Devignot, Stéphanie, Åkerström, Sara, Karlberg, Helen, Wattrang, Eva, Bereczky, Sándor, Mousavi-Jazi, Mehrdad, Risinger, Christian Walter, Lindegren, Gunnel, Vernersson, Caroline, Paweska, Janusz, van Vuren, Petrus Jansen, Blixt, Klas Ola, Brun, Alejandro, Friedemann, Weber, and Mirazimi, Ali

Abstract

Crimean-Congo hemorrhagic fever virus (CCHFV) is a bunyavirus causing severe hemorrhagic fever disease in humans, with high mortality rates. The requirement of a high-containment laboratory and the lack of an animal model hampered the study of the immune response and protection of vaccine candidates. Using the recently developed interferon alpha receptor knockout (IFNAR-/-) mouse model, which replicates human disease, we investigated the immunogenicity and protection of two novel CCHFV vaccine candidates: a DNA vaccine encoding a ubiquitin-linked version of CCHFV Gc, Gn, and N and one using transcriptionally competent virus-like particles (tc-VLPs). In contrast to most studies that focus on neutralizing antibodies, we measured both humoral and cellular immune responses. We demonstrated a clear and 100% efficient preventive immunity against lethal CCHFV challenge with the DNA vaccine. Interestingly, there was no correlation with the neutralizing antibody titers alone, which were higher in the tc-VLP-vaccinated mice. However, the animals with a lower neutralizing titer, but a dominant cell-mediated Th1 response and a balanced Th2 response, resisted the CCHFV challenge. Moreover, we found that in challenged mice with a Th1 response (immunized by DNA/DNA and boosted by tc-VLPs), the immune response changed to Th2 at day 9 postchallenge. In addition, we were able to identify new linear B-cell epitope regions that are highly conserved between CCHFV strains. Altogether, our results suggest that a predominantly Th1-type immune response provides the most efficient protective immunity against CCHFV challenge. However, we cannot exclude the importance of the neutralizing antibodies as the surviving immunized mice exhibited substantial amounts of them.

Published
2017

7. Immunization with DNA plasmids coding for crimean-congo hemorrhagic fever virus capsid and envelope proteins and/or virus-like particles induces protection and survival in challenged mice

Author

Hinkula, Jorma, Devignot, Stéphanie, Åkerström, Sara, Karlberg, Helen, Wattrang, Eva, Bereczky, Sándor, Mousavi-Jazi, Mehrdad, Risinger, Christian Walter, Lindegren, Gunnel, Vernersson, Caroline, Paweska, Janusz, van Vuren, Petrus Jansen, Blixt, Klas Ola, Brun, Alejandro, Friedemann, Weber, Mirazimi, Ali, Hinkula, Jorma, Devignot, Stéphanie, Åkerström, Sara, Karlberg, Helen, Wattrang, Eva, Bereczky, Sándor, Mousavi-Jazi, Mehrdad, Risinger, Christian Walter, Lindegren, Gunnel, Vernersson, Caroline, Paweska, Janusz, van Vuren, Petrus Jansen, Blixt, Klas Ola, Brun, Alejandro, Friedemann, Weber, and Mirazimi, Ali

Abstract

Crimean-Congo hemorrhagic fever virus (CCHFV) is a bunyavirus causing severe hemorrhagic fever disease in humans, with high mortality rates. The requirement of a high-containment laboratory and the lack of an animal model hampered the study of the immune response and protection of vaccine candidates. Using the recently developed interferon alpha receptor knockout (IFNAR-/-) mouse model, which replicates human disease, we investigated the immunogenicity and protection of two novel CCHFV vaccine candidates: a DNA vaccine encoding a ubiquitin-linked version of CCHFV Gc, Gn, and N and one using transcriptionally competent virus-like particles (tc-VLPs). In contrast to most studies that focus on neutralizing antibodies, we measured both humoral and cellular immune responses. We demonstrated a clear and 100% efficient preventive immunity against lethal CCHFV challenge with the DNA vaccine. Interestingly, there was no correlation with the neutralizing antibody titers alone, which were higher in the tc-VLP-vaccinated mice. However, the animals with a lower neutralizing titer, but a dominant cell-mediated Th1 response and a balanced Th2 response, resisted the CCHFV challenge. Moreover, we found that in challenged mice with a Th1 response (immunized by DNA/DNA and boosted by tc-VLPs), the immune response changed to Th2 at day 9 postchallenge. In addition, we were able to identify new linear B-cell epitope regions that are highly conserved between CCHFV strains. Altogether, our results suggest that a predominantly Th1-type immune response provides the most efficient protective immunity against CCHFV challenge. However, we cannot exclude the importance of the neutralizing antibodies as the surviving immunized mice exhibited substantial amounts of them.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results